Fennec Pharmaceuticals Inc.

NasdaqCM:FENC 株式レポート

時価総額:US$119.0m

Fennec Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /16

Fennec Pharmaceuticalsの総株主資本は$-1.4M 、総負債は$31.8Mで、負債比率は-2341.6%となります。総資産と総負債はそれぞれ$63.2Mと$64.5Mです。 Fennec Pharmaceuticalsの EBIT は$5.9Mで、利息カバレッジ比率1.9です。現金および短期投資は$43.1Mです。

主要情報

-2,341.6%

負債資本比率

US$31.78m

負債

インタレスト・カバレッジ・レシオ1.9x
現金US$43.05m
エクイティ-US$1.36m
負債合計US$64.52m
総資産US$63.16m

財務の健全性に関する最新情報

Recent updates

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Could See Upside If Pedmark Gets Approved

Jul 29

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow

Jun 18

Fennec Pharma resubmits PEDMARK application in U.S.

May 28

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01
Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Mar 02
Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?

Jan 26
Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?

Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth

Dec 22
Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth

財務状況分析

短期負債: FENCは マイナスの株主資本 を有しており、これは 短期資産短期負債 をカバーしていないことよりも深刻な状況です。

長期負債: FENCは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。


デット・ツー・エクイティの歴史と分析

負債レベル: FENCは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。

負債の削減: FENCの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。

債務返済能力: FENCの負債は 営業キャッシュフロー によって 十分にカバー されています ( 72.5% )。

インタレストカバレッジ: FENCの負債に対する 利息支払いEBIT ( 1.9 x coverage) によって 十分にカバーされていません


貸借対照表


健全な企業の発掘